Cargando…
A Cyclic Peptidic Serine Protease Inhibitor: Increasing Affinity by Increasing Peptide Flexibility
Peptides are attracting increasing interest as protease inhibitors. Here, we demonstrate a new inhibitory mechanism and a new type of exosite interactions for a phage-displayed peptide library-derived competitive inhibitor, mupain-1 (CPAYSRYLDC), of the serine protease murine urokinase-type plasmino...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278837/ https://www.ncbi.nlm.nih.gov/pubmed/25545505 http://dx.doi.org/10.1371/journal.pone.0115872 |
_version_ | 1782350583613620224 |
---|---|
author | Zhao, Baoyu Xu, Peng Jiang, Longguang Paaske, Berit Kromann-Hansen, Tobias Jensen, Jan K. Sørensen, Hans Peter Liu, Zhuo Nielsen, Jakob T. Christensen, Anni Hosseini, Masood Sørensen, Kasper K. Nielsen, Niels Christian Jensen, Knud J. Huang, Mingdong Andreasen, Peter A. |
author_facet | Zhao, Baoyu Xu, Peng Jiang, Longguang Paaske, Berit Kromann-Hansen, Tobias Jensen, Jan K. Sørensen, Hans Peter Liu, Zhuo Nielsen, Jakob T. Christensen, Anni Hosseini, Masood Sørensen, Kasper K. Nielsen, Niels Christian Jensen, Knud J. Huang, Mingdong Andreasen, Peter A. |
author_sort | Zhao, Baoyu |
collection | PubMed |
description | Peptides are attracting increasing interest as protease inhibitors. Here, we demonstrate a new inhibitory mechanism and a new type of exosite interactions for a phage-displayed peptide library-derived competitive inhibitor, mupain-1 (CPAYSRYLDC), of the serine protease murine urokinase-type plasminogen activator (uPA). We used X-ray crystal structure analysis, site-directed mutagenesis, liquid state NMR, surface plasmon resonance analysis, and isothermal titration calorimetry and wild type and engineered variants of murine and human uPA. We demonstrate that Arg(6) inserts into the S1 specificity pocket, its carbonyl group aligning improperly relative to Ser(195) and the oxyanion hole, explaining why the peptide is an inhibitor rather than a substrate. Substitution of the P1 Arg with novel unnatural Arg analogues with aliphatic or aromatic ring structures led to an increased affinity, depending on changes in both P1 - S1 and exosite interactions. Site-directed mutagenesis showed that exosite interactions, while still supporting high affinity binding, differed substantially between different uPA variants. Surprisingly, high affinity binding was facilitated by Ala-substitution of Asp(9) of the peptide, in spite of a less favorable binding entropy and loss of a polar interaction. We conclude that increased flexibility of the peptide allows more favorable exosite interactions, which, in combination with the use of novel Arg analogues as P1 residues, can be used to manipulate the affinity and specificity of this peptidic inhibitor, a concept different from conventional attempts at improving inhibitor affinity by reducing the entropic burden. |
format | Online Article Text |
id | pubmed-4278837 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-42788372015-01-05 A Cyclic Peptidic Serine Protease Inhibitor: Increasing Affinity by Increasing Peptide Flexibility Zhao, Baoyu Xu, Peng Jiang, Longguang Paaske, Berit Kromann-Hansen, Tobias Jensen, Jan K. Sørensen, Hans Peter Liu, Zhuo Nielsen, Jakob T. Christensen, Anni Hosseini, Masood Sørensen, Kasper K. Nielsen, Niels Christian Jensen, Knud J. Huang, Mingdong Andreasen, Peter A. PLoS One Research Article Peptides are attracting increasing interest as protease inhibitors. Here, we demonstrate a new inhibitory mechanism and a new type of exosite interactions for a phage-displayed peptide library-derived competitive inhibitor, mupain-1 (CPAYSRYLDC), of the serine protease murine urokinase-type plasminogen activator (uPA). We used X-ray crystal structure analysis, site-directed mutagenesis, liquid state NMR, surface plasmon resonance analysis, and isothermal titration calorimetry and wild type and engineered variants of murine and human uPA. We demonstrate that Arg(6) inserts into the S1 specificity pocket, its carbonyl group aligning improperly relative to Ser(195) and the oxyanion hole, explaining why the peptide is an inhibitor rather than a substrate. Substitution of the P1 Arg with novel unnatural Arg analogues with aliphatic or aromatic ring structures led to an increased affinity, depending on changes in both P1 - S1 and exosite interactions. Site-directed mutagenesis showed that exosite interactions, while still supporting high affinity binding, differed substantially between different uPA variants. Surprisingly, high affinity binding was facilitated by Ala-substitution of Asp(9) of the peptide, in spite of a less favorable binding entropy and loss of a polar interaction. We conclude that increased flexibility of the peptide allows more favorable exosite interactions, which, in combination with the use of novel Arg analogues as P1 residues, can be used to manipulate the affinity and specificity of this peptidic inhibitor, a concept different from conventional attempts at improving inhibitor affinity by reducing the entropic burden. Public Library of Science 2014-12-29 /pmc/articles/PMC4278837/ /pubmed/25545505 http://dx.doi.org/10.1371/journal.pone.0115872 Text en © 2014 Zhao et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Zhao, Baoyu Xu, Peng Jiang, Longguang Paaske, Berit Kromann-Hansen, Tobias Jensen, Jan K. Sørensen, Hans Peter Liu, Zhuo Nielsen, Jakob T. Christensen, Anni Hosseini, Masood Sørensen, Kasper K. Nielsen, Niels Christian Jensen, Knud J. Huang, Mingdong Andreasen, Peter A. A Cyclic Peptidic Serine Protease Inhibitor: Increasing Affinity by Increasing Peptide Flexibility |
title | A Cyclic Peptidic Serine Protease Inhibitor: Increasing Affinity by Increasing Peptide Flexibility |
title_full | A Cyclic Peptidic Serine Protease Inhibitor: Increasing Affinity by Increasing Peptide Flexibility |
title_fullStr | A Cyclic Peptidic Serine Protease Inhibitor: Increasing Affinity by Increasing Peptide Flexibility |
title_full_unstemmed | A Cyclic Peptidic Serine Protease Inhibitor: Increasing Affinity by Increasing Peptide Flexibility |
title_short | A Cyclic Peptidic Serine Protease Inhibitor: Increasing Affinity by Increasing Peptide Flexibility |
title_sort | cyclic peptidic serine protease inhibitor: increasing affinity by increasing peptide flexibility |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278837/ https://www.ncbi.nlm.nih.gov/pubmed/25545505 http://dx.doi.org/10.1371/journal.pone.0115872 |
work_keys_str_mv | AT zhaobaoyu acyclicpeptidicserineproteaseinhibitorincreasingaffinitybyincreasingpeptideflexibility AT xupeng acyclicpeptidicserineproteaseinhibitorincreasingaffinitybyincreasingpeptideflexibility AT jianglongguang acyclicpeptidicserineproteaseinhibitorincreasingaffinitybyincreasingpeptideflexibility AT paaskeberit acyclicpeptidicserineproteaseinhibitorincreasingaffinitybyincreasingpeptideflexibility AT kromannhansentobias acyclicpeptidicserineproteaseinhibitorincreasingaffinitybyincreasingpeptideflexibility AT jensenjank acyclicpeptidicserineproteaseinhibitorincreasingaffinitybyincreasingpeptideflexibility AT sørensenhanspeter acyclicpeptidicserineproteaseinhibitorincreasingaffinitybyincreasingpeptideflexibility AT liuzhuo acyclicpeptidicserineproteaseinhibitorincreasingaffinitybyincreasingpeptideflexibility AT nielsenjakobt acyclicpeptidicserineproteaseinhibitorincreasingaffinitybyincreasingpeptideflexibility AT christensenanni acyclicpeptidicserineproteaseinhibitorincreasingaffinitybyincreasingpeptideflexibility AT hosseinimasood acyclicpeptidicserineproteaseinhibitorincreasingaffinitybyincreasingpeptideflexibility AT sørensenkasperk acyclicpeptidicserineproteaseinhibitorincreasingaffinitybyincreasingpeptideflexibility AT nielsennielschristian acyclicpeptidicserineproteaseinhibitorincreasingaffinitybyincreasingpeptideflexibility AT jensenknudj acyclicpeptidicserineproteaseinhibitorincreasingaffinitybyincreasingpeptideflexibility AT huangmingdong acyclicpeptidicserineproteaseinhibitorincreasingaffinitybyincreasingpeptideflexibility AT andreasenpetera acyclicpeptidicserineproteaseinhibitorincreasingaffinitybyincreasingpeptideflexibility AT zhaobaoyu cyclicpeptidicserineproteaseinhibitorincreasingaffinitybyincreasingpeptideflexibility AT xupeng cyclicpeptidicserineproteaseinhibitorincreasingaffinitybyincreasingpeptideflexibility AT jianglongguang cyclicpeptidicserineproteaseinhibitorincreasingaffinitybyincreasingpeptideflexibility AT paaskeberit cyclicpeptidicserineproteaseinhibitorincreasingaffinitybyincreasingpeptideflexibility AT kromannhansentobias cyclicpeptidicserineproteaseinhibitorincreasingaffinitybyincreasingpeptideflexibility AT jensenjank cyclicpeptidicserineproteaseinhibitorincreasingaffinitybyincreasingpeptideflexibility AT sørensenhanspeter cyclicpeptidicserineproteaseinhibitorincreasingaffinitybyincreasingpeptideflexibility AT liuzhuo cyclicpeptidicserineproteaseinhibitorincreasingaffinitybyincreasingpeptideflexibility AT nielsenjakobt cyclicpeptidicserineproteaseinhibitorincreasingaffinitybyincreasingpeptideflexibility AT christensenanni cyclicpeptidicserineproteaseinhibitorincreasingaffinitybyincreasingpeptideflexibility AT hosseinimasood cyclicpeptidicserineproteaseinhibitorincreasingaffinitybyincreasingpeptideflexibility AT sørensenkasperk cyclicpeptidicserineproteaseinhibitorincreasingaffinitybyincreasingpeptideflexibility AT nielsennielschristian cyclicpeptidicserineproteaseinhibitorincreasingaffinitybyincreasingpeptideflexibility AT jensenknudj cyclicpeptidicserineproteaseinhibitorincreasingaffinitybyincreasingpeptideflexibility AT huangmingdong cyclicpeptidicserineproteaseinhibitorincreasingaffinitybyincreasingpeptideflexibility AT andreasenpetera cyclicpeptidicserineproteaseinhibitorincreasingaffinitybyincreasingpeptideflexibility |